Shares of Bayer BAYRY gained 12.1% after the Solicitor General supported a Supreme Court review of its Roundup weedkiller ...

Bayer AG BAYRY announced that pipeline candidate asundexian met primary efficacy and safety endpoints in late-stage OCEANIC-STROKE Study in secondary stroke prevention. Results from the study showed ...

More changes are coming from the Food and Drug Administration as officials move to get rid of warning labels on some ...

In a closely watched case, the U.S. solicitor general urged the Supreme Court to review a controversy over so-called skinny ...

The drugs have soared in popularity, with some men taking them for unapproved uses like anti-aging or increasing muscle mass.

The drugs are essentially laboratory-made versions of natural antibodies that help the immune system fight off RSV. The FDA ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The FDA has restricted the type ...

Bayer recently reported its third-quarter 2025 results, highlighted by a 20.8% increase in adjusted operating income largely driven by its Crop Science division, as well as new late-breaking Phase III ...

Alert FDA Approves Third-Ever Drug for Lupus Nephritis Obinutuzumab (Gazyva) is the first drug to be approved for lupus nephritis since the approvals of belimumab (Benlysta) in 2020 and voclosporin ...

Alert Rejected cGvHD Therapy Gets Second Look by EMA The EMA initially rejected Rezurock due to uncertainty over its clinical benefit, noting that the pivotal study had no comparator arm and permitted ...